Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about Apolipoprotein E lipid transport: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
| Target | Relation | Type | Str |
|---|---|---|---|
| No outgoing edges | |||
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Selective APOE4 Degradation via Proteolysis Targeting Chimer | 0.795 | neurodegeneration | APOE4 structural biology and therapeutic |
| Competitive APOE4 Domain Stabilization Peptides | 0.784 | neurodegeneration | APOE4 structural biology and therapeutic |
| APOE4 Allosteric Rescue via Small Molecule Chaperones | 0.765 | neurodegeneration | APOE4 structural biology and therapeutic |
| Targeted APOE4-to-APOE3 Base Editing Therapy | 0.758 | neurodegeneration | APOE4 structural biology and therapeutic |
| Interfacial Lipid Mimetics to Disrupt Domain Interaction | 0.723 | neurodegeneration | APOE4 structural biology and therapeutic |
| Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides | 0.718 | neurodegeneration | Blood-brain barrier transport mechanisms |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.773
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| GWAS of plasma NfL in East Asian cohort | exploratory | Alzheimer's disease | 0.950 | 0.00 | human patients - East Asian co | proposed | N/A |
| GWAS of plasma pTau217 in East Asian cohort | exploratory | Alzheimer's disease | 0.950 | 0.00 | human patients - East Asian co | proposed | N/A |
| Dairy intake and dementia risk in Malmö Diet and Cancer cohort | clinical | Alzheimer's disease | 0.950 | 0.00 | Swedish community-based adults | proposed | N/A |
| GWAS of plasma pTau181 in East Asian cohort | exploratory | Alzheimer's disease | 0.950 | 0.00 | human patients - East Asian co | proposed | N/A |
| GWAS of plasma GFAP in East Asian cohort | exploratory | Alzheimer's disease | 0.950 | 0.00 | human patients - East Asian co | proposed | N/A |
| KEEPS Continuation: Long-term effects of menopausal hormone therapy on | clinical | Alzheimer's disease | 0.950 | 0.00 | recently menopausal women with | proposed | N/A |
| GWAS of composite biomarker score | exploratory | Alzheimer's disease | 0.900 | 0.00 | human patients - East Asian co | proposed | N/A |
| RBG treatment in ApoE-/- atherosclerosis mouse model | validation | atherosclerosis | 0.900 | 0.00 | ApoE-/- mice | proposed | N/A |
| APOE4 association with TDP-43 pathology in AD | exploratory | Alzheimer's disease | 0.750 | 0.00 | human patients | proposed | N/A |
| s:** - Biochemical binding assays measuring PROTAC selectivity for APO | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $100,000 |
| Why Does Amyloid Removal Only Slow Decline 27%? — Mechanistic investig | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $7,100,000 |
| AD Combination Therapy Trial: Anti-Aβ + Anti-Tau | clinical | Alzheimer's Disease | 0.400 | 0.50 | cell_line | proposed | $180,000 |
| ApoE4 Function in Alzheimer's Disease | validation | Alzheimer's Disease | 0.400 | 0.50 | mouse | proposed | $360,000 |
| Biomarker-Guided Sequential Therapy Selection in Alzheimer's Disease | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Blood-Based Biomarker Panel for Early AD Detection | clinical | Alzheimer's Disease | 0.400 | 0.50 | cell_line | proposed | $220,000 |
| CRISPR Gene Correction Approaches for CBS/PSP | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Down Syndrome Alzheimer's Disease: Mechanisms and Therapeutic Timing | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $7,500,000 |
| Sex Differences in Alzheimer's Disease — mechanisms and therapeutic im | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $7,500,000 |
| AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Positive Indiv | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Metal Ion Homeostasis Dysregulation in Alzheimer's Disease | validation | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $2,730,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of [PMID:30335591] | Rusmini P, Cortese K, Crippa V, Cristofa | Autophagy | 2019 | 2 |
| Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegenerat [PMID:37995685] | Litvinchuk A, Suh JH, Guo JL, Lin K, Dav | Neuron | 2024 | 1 |
| An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wid [PMID:38753766] | Huang Q, Chan KY, Wu J, Botticello-Romer | Science | 2024 | 1 |
| The cell biology of APOE in the brain. [PMID:37805344] | Windham IA, Cohen S | Trends Cell Biol | 2024 | 1 |
| The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegene [PMID:37957317] | Maxine R Nelson, Peng Liu, Ayushi Agrawa | Nature neuroscience | 2023 | 1 |
| Interplay of Low-Density Lipoprotein Receptors, LRPs, and Lipoproteins in Pulmon [PMID:35257044] | Calvier L, Herz J, Hansmann G | JACC Basic Transl Sci | 2022 | 1 |
| ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies. [PMID:36348357] | Raulin AC, Doss SV, Trottier ZA, Ikezu T | Mol Neurodegener | 2022 | 1 |
| APOE4 disrupts intracellular lipid homeostasis in human iPSC-derived glia. [PMID:33658354] | Sienski G, Narayan P, Bonner JM, Kory N, | Sci Transl Med | 2021 | 1 |
| APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therape [PMID:33340485] | Serrano-Pozo A, Das S, Hyman BT | Lancet Neurol | 2021 | 1 |
| Lysosome-targeting chimaeras for degradation of extracellular proteins. [PMID:32728216] | Banik SM, Pedram K, Wisnovsky S, Ahn G, | Nature | 2020 | 1 |
| Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. [PMID:31564456] | Long JM, Holtzman DM | Cell | 2019 | 1 |
| Myeloid-Specific Deletion of Epsins 1 and 2 Reduces Atherosclerosis by Preventin [PMID:30595089] | Brophy ML, Dong Y, Tao H, Yancey PG, Son | Circ Res | 2019 | 1 |
| Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. [PMID:31367008] | Yamazaki Y, Zhao N, Caulfield TR, Liu CC | Nat Rev Neurol | 2019 | 1 |
| The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Mic [PMID:28930663] | Krasemann S, Madore C, Cialic R, Baufeld | Immunity | 2017 | 1 |
| Role of LRP1 in the pathogenesis of Alzheimer's disease: evidence from clinical [PMID:28381441] | Shinohara M, Tachibana M, Kanekiyo T, Bu | J Lipid Res | 2017 | 1 |
| Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associate [PMID:41905188] | Cetindag AC, Schipke CG, Esselmann H, Kr | The journal of prevention of A | 2026 | 0 |
| Modulation of apolipoprotein E receptor-2 by ApoE4, amyloid β-peptide, reelin, a [PMID:41858499] | ["Barger S", "Moerman-Herzog A"] | Frontiers in molecular neurosc | 2026 | 0 |
| ASS1 Promotes Atherosclerotic Inflammation Through the NLRP3/IL-33/ST2 Axis in O [PMID:41914296] | Wu S, Han F, Qiao Z, Yuan S, Bian X, Zha | Frontiers in bioscience (Landm | 2026 | 0 |
| CRISPR-based correction of apolipoprotein E4 in Alzheimer's disease: Therapeutic [PMID:41812941] | ["Wang M", "Niu D", "Zhang Q", "Tang Y", | International journal of biolo | 2026 | 0 |
| Multimodal biomarker AI techniques for early neurocognitive disorder diagnosis: [PMID:41921464] | Catino F, Castellana F, Zupo R, Giannocc | Artificial intelligence in med | 2026 | 0 |
Multi-agent debates referencing this entity